Contract 36F79723D0039

Accord Biopharma, Inc. · Department Of Veterans Affairs · July 29, 2025

Fixed Price With Economic Price AdjustmentFull & Open CompetitionNAICS 325412

Accord Biopharma, Inc. was awarded a federal contract by Department Of Veterans Affairs on July 29, 2025 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 9 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on January 26, 2026. If all options are exercised, the contract could reach $300,000.

Potential value
$300.0K
if all options exercised
Modifications
9
Latest January 26, 2026

Contract details

PIID
36F79723D0039
Award type
Pricing
Fixed Price With Economic Price Adjustment
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
325412 · Pharmaceutical Preparation Manufacturing
Product / service
Drugs And Biologicals
First action
July 29, 2025
Latest action
January 26, 2026

Description

PRODUCT LIFE CYCLE

Modification timeline

  • January 26, 2026
    Mod P00017 · Supplemental Agreement For Work Within Scope
    $0
  • January 22, 2026
    Mod P00014 · Supplemental Agreement For Work Within Scope
    NDC CHANGE
    $0
  • January 22, 2026
    Mod P00012 · Supplemental Agreement For Work Within Scope
    NDC CHANGE
    $0
  • January 14, 2026
    Mod P00015 · Supplemental Agreement For Work Within Scope
    TEMPORARY PRICE REDUCTION
    $0
  • December 13, 2025
    Mod P00013 · Supplemental Agreement For Work Within Scope
    2026 PUBLIC LAW UPDATE
    $0
  • November 13, 2025
    Mod P00011 · Supplemental Agreement For Work Within Scope
    $0
  • October 1, 2025
    Mod P00010 · Supplemental Agreement For Work Within Scope
    PRODUCT ADDITION
    $0
  • September 29, 2025
    Mod P00009 · Supplemental Agreement For Work Within Scope
    TEMPORARY PRICE REDUCTION
    $0
  • August 12, 2025
    Mod P00008 · Supplemental Agreement For Work Within Scope
    NDC CHANGE
    $0
  • July 29, 2025
    Mod P00006 · Supplemental Agreement For Work Within Scope
    ADDITION
    $0

Similar contracts

RecipientAgencyDateObligated
Petnet Solutions, Inc.Department Of Veterans AffairsApril 1, 2026$387.4K
Eli Lilly And CompanyDepartment Of Veterans AffairsApril 1, 2026$0
Exelan Pharmaceuticals IncDepartment Of Veterans AffairsApril 1, 2026$0
Cardinal Health 414, LlcDepartment Of Veterans AffairsApril 1, 2026$122.9K
Guardian Pharmacy Of Indianapolis Nuclear, LlcDepartment Of Veterans AffairsApril 1, 2026$0
Jubilant Draximage IncDepartment Of Veterans AffairsApril 1, 2026$0

Top contractors in NAICS 325412

Lifetime obligated dollars across all federal contracts in this NAICS code.

#ContractorContractsObligated
1Mckesson Corporation1,187$4.96B
2Merck Sharp & Dohme Llc26$894.71M
3Sanofi Vaccines Us Inc.57$702.38M
4Pfizer Inc169$541.15M
5Glaxosmithkline, Llc14$505.04M
6Phlow Corp.1$105.27M
7Exelan Pharmaceuticals Inc76$104.30M
8Seqirus USA Inc47$59.15M
9Emergent Biosolutions Canada Inc2$53.73M
10Mckesson Specialty Distribution Llc1$51.05M

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract 36F79723D0039?

Contract 36F79723D0039 is a federal contract awarded to Accord Biopharma, Inc. by Department Of Veterans Affairs on July 29, 2025 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 9 times since the base award.

Who won contract 36F79723D0039?

Accord Biopharma, Inc. won contract 36F79723D0039 from Department Of Veterans Affairs.

How much is contract 36F79723D0039 worth?

Contract 36F79723D0039 has obligated $0 to date but carries a potential ceiling of $300,000 if fully funded and all options are exercised.